CIK 0001980845 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events
- 8-K Event Shareholder vote results
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- ARS Other Annual Report to Security Holders
- DEF 14A Proxy Proxy Statement
- 8-K Event Executive or director change · Regulation FD disclosure · Other events
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Bylaws or fiscal year change · Regulation FD disclosure
- S-8 Other Securities Offered to Employees in Benefit Plans
- 424B5 Offering Prospectus
- 8-K Event Material agreement · Agreement ended
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
Page 2 of 14 · 268 filings